Joshua Fitch

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

This combination vaccine candidate, with a safety profile consistent with Pfizer’s COVID-19 vaccine, will most likely be moving to a phase 3 trial in the coming months.

FDA approved emergency use of Novavax COVID-19 vaccine (NVX-CoV2601) for ages 12 years and older. It also protects against current variants.

According to a recent Morbidity and Mortality Weekly Report, the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Pfizer's Abrysvo vaccine prevents RSV-induced LRTD in infants. It's given as a single-dose injection to pregnant individuals between 32 to 36 weeks of gestation.